These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

416 related articles for article (PubMed ID: 33278025)

  • 21. In vivo hippocampal microdialysis reveals impairment of NMDA receptor-cGMP signaling in APP(SW) and APP(SW)/PS1(L166P) Alzheimer's transgenic mice.
    Duszczyk M; Kuszczyk M; Guridi M; Lazarewicz JW; Sadowski MJ
    Neurochem Int; 2012 Dec; 61(7):976-80. PubMed ID: 22841892
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Evaluation of the safety, tolerability, and efficacy of pimavanserin versus placebo in patients with Alzheimer's disease psychosis: a phase 2, randomised, placebo-controlled, double-blind study.
    Ballard C; Banister C; Khan Z; Cummings J; Demos G; Coate B; Youakim JM; Owen R; Stankovic S;
    Lancet Neurol; 2018 Mar; 17(3):213-222. PubMed ID: 29452684
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pimavanserin use in a movement disorders clinic: a single-center experience.
    Mahajan A; Bulica B; Ahmad A; Kaminski P; LeWitt P; Taylor D; Krstevska S; Patel N
    Neurol Sci; 2018 Oct; 39(10):1767-1771. PubMed ID: 30032332
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A Retrospective Study of Pimavanserin Use in a Movement Disorders Clinic.
    Friedman JH
    Clin Neuropharmacol; 2017; 40(4):157-159. PubMed ID: 28622212
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Nighttime Sleep and Daytime Sleepiness Improved With Pimavanserin During Treatment of Parkinson's Disease Psychosis.
    Patel N; LeWitt P; Neikrug AB; Kesslak P; Coate B; Ancoli-Israel S
    Clin Neuropharmacol; 2018; 41(6):210-215. PubMed ID: 30303817
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Changing the treatment paradigm for Parkinson's disease psychosis with pimavanserin.
    Lyons KE; Pahwa R; Hermanowicz N; Davis T; Pagan F; Isaacson S
    Expert Rev Clin Pharmacol; 2019 Jul; 12(7):681-691. PubMed ID: 31159608
    [No Abstract]   [Full Text] [Related]  

  • 27. Serotonin signaling is associated with lower amyloid-β levels and plaques in transgenic mice and humans.
    Cirrito JR; Disabato BM; Restivo JL; Verges DK; Goebel WD; Sathyan A; Hayreh D; D'Angelo G; Benzinger T; Yoon H; Kim J; Morris JC; Mintun MA; Sheline YI
    Proc Natl Acad Sci U S A; 2011 Sep; 108(36):14968-73. PubMed ID: 21873225
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pimavanserin for the treatment of Parkinson's disease psychosis.
    Chendo I; Ferreira JJ
    Expert Opin Pharmacother; 2016 Oct; 17(15):2115-24. PubMed ID: 27609312
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effects of growth hormone-releasing hormone on sleep and brain interstitial fluid amyloid-β in an APP transgenic mouse model.
    Liao F; Zhang TJ; Mahan TE; Jiang H; Holtzman DM
    Brain Behav Immun; 2015 Jul; 47():163-71. PubMed ID: 25218899
    [TBL] [Abstract][Full Text] [Related]  

  • 30. M1 muscarinic agonists can modulate some of the hallmarks in Alzheimer's disease: implications in future therapy.
    Fisher A; Pittel Z; Haring R; Bar-Ner N; Kliger-Spatz M; Natan N; Egozi I; Sonego H; Marcovitch I; Brandeis R
    J Mol Neurosci; 2003; 20(3):349-56. PubMed ID: 14501019
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Successful treatment of clozapine-nonresponsive refractory hallucinations and delusions with pimavanserin, a serotonin 5HT-2A receptor inverse agonist.
    Nasrallah HA; Fedora R; Morton R
    Schizophr Res; 2019 Jun; 208():217-220. PubMed ID: 30837203
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Opposing synaptic regulation of amyloid-β metabolism by NMDA receptors in vivo.
    Verges DK; Restivo JL; Goebel WD; Holtzman DM; Cirrito JR
    J Neurosci; 2011 Aug; 31(31):11328-37. PubMed ID: 21813692
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Pimavanserin for the treatment of Parkinson's disease psychosis: number needed to treat, number needed to harm, and likelihood to be helped or harmed.
    Citrome L; Norton JC; Chi-Burris K; Demos G
    CNS Spectr; 2018 Jun; 23(3):228-238. PubMed ID: 29098976
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Reduction of beta-amyloid pathology by celastrol in a transgenic mouse model of Alzheimer's disease.
    Paris D; Ganey NJ; Laporte V; Patel NS; Beaulieu-Abdelahad D; Bachmeier C; March A; Ait-Ghezala G; Mullan MJ
    J Neuroinflammation; 2010 Mar; 7():17. PubMed ID: 20211007
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Attenuation of phencyclidine-induced object recognition deficits by the combination of atypical antipsychotic drugs and pimavanserin (ACP 103), a 5-hydroxytryptamine(2A) receptor inverse agonist.
    Snigdha S; Horiguchi M; Huang M; Li Z; Shahid M; Neill JC; Meltzer HY
    J Pharmacol Exp Ther; 2010 Feb; 332(2):622-31. PubMed ID: 19864614
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Improving the treatment of Parkinson's disease: Structure-based development of novel 5-HT
    Ma M; Yang Y; Du G; Dai Y; Zhu X; Wang W; Xu H; Zhang J; Zheng L; Zou F; Yang H; Liu B; Liu W; Ye L; Zhang R; Tian J
    Eur J Med Chem; 2022 Apr; 234():114246. PubMed ID: 35279606
    [TBL] [Abstract][Full Text] [Related]  

  • 37. In vivo assessment of brain interstitial fluid with microdialysis reveals plaque-associated changes in amyloid-beta metabolism and half-life.
    Cirrito JR; May PC; O'Dell MA; Taylor JW; Parsadanian M; Cramer JW; Audia JE; Nissen JS; Bales KR; Paul SM; DeMattos RB; Holtzman DM
    J Neurosci; 2003 Oct; 23(26):8844-53. PubMed ID: 14523085
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cerebrolysin decreases amyloid-beta production by regulating amyloid protein precursor maturation in a transgenic model of Alzheimer's disease.
    Rockenstein E; Torrance M; Mante M; Adame A; Paulino A; Rose JB; Crews L; Moessler H; Masliah E
    J Neurosci Res; 2006 May; 83(7):1252-61. PubMed ID: 16511867
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Pimavanserin: First Global Approval.
    Markham A
    Drugs; 2016 Jul; 76(10):1053-7. PubMed ID: 27262680
    [TBL] [Abstract][Full Text] [Related]  

  • 40. 5‑Hydroxytryptamine 2A receptor inverse agonist pimavanserin impairs maternal behavior in postpartum female rats.
    Gan L; Sun M; Chen W
    Pharmacol Biochem Behav; 2018 Dec; 175():152-159. PubMed ID: 30393120
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 21.